Pellet, useful to prepare pharmaceutical preparations and administer therapeutically and/or prophylactically active substances e.g. antirheumatic-, antidiabetic- or antiallergic- drug, comprises a water-soluble carrier e.g. mannitol

摘要

Pellet (A) (with length-width-ratio of less than 1.4) comprises a water-soluble carrier, where (A) disintegrates under visually detectable loss of pellet structure into smaller fragments in a test carried out by: adding a pellet with demineralized water into a petri dish; subsequently fixing the petri dish directly on the measuring cylinder of a stampf volumeter; and subsequently the pellets are directly photographed. Pellet (A) (with length-width-ratio of less than 1.4) comprises a water-soluble carrier, where (A) disintegrates under visually detectable loss of pellet structure into smaller fragments in a test carried out by: (a) adding a pellet (200-800 mg) with demineralized water (0.5 ml) to a petri dish; (b) subsequently fixing the petri dish directly on the measuring cylinder of a stampf volumeter; (c) after 10 seconds, 30 stampf pitching is carried out; and (d) subsequently the pellets are directly photographed. Independent claims are also included for: (1) a pellet product (B), where at least 90% of it is similar to (A); (2) a pellet product comprising a majority of pellets, which comprise a core containing a water-soluble carrier and where at least 90% of the pellets show a length-width-ratio of less than about 1.4, where the decay time of the pellet product measured in a decay tester with sieve base amounts to less than 1:30 minutes; (3) a pellet product comprising majority of pellets, where the pellet core contains the water-soluble carrier and where 90% of the pellets show a length-width-ratio of less than about 1.4, where the pellet product in a sensory test is classified into 0 (that is equal to no foreign body feeling), 1 (that is equal to pulpy and soft), 2 (that is equal to sandy), 3 (that is equal to granular), where the second classification forms the majority after estimation at 5 seconds in at least 10 test persons; (4) the preparations of (A) and (B); (5) a pharmaceutical pellet (C) comprising (A) as a core and one or more layers of core, which contains at least an active agent; and a pharmaceutical pellet product comprising (C).